Peptonic Medical (PMED) Q3 2025 earnings summary

Executive summary

• Strategic restructuring completed, with Israeli and Finnish subsidiaries divested and product lines streamlined to focus on core intimate care portfolio.

• Distribution agreement signed for USA, Canada, Mexico, and UK, with first order received post-period.

• Ongoing corporate reorganization, with a reconstruction plan submitted and creditor meeting scheduled for November 2025.

Financial highlights

• Q3 2025 sales of goods: 2,579 KSEK, down 53% year-over-year due to structural changes.

• Q3 gross profit: 1,138 KSEK (gross margin 44%), impacted by inventory write-downs.

• Q3 operating result: -9,498 KSEK, improved from -10,491 KSEK year-over-year.

• Nine-month sales: 11,249 KSEK, down from 22,446 KSEK year-over-year.

• Cash at period end: 908 KSEK, down from 8,206 KSEK year-over-year.

Outlook and guidance

• Focus on expanding presence in the UK and North America through new distribution partnerships.

• Reconstruction plan includes capital raise and debt settlement, pending court and creditor approval.